Formulation and Evaluation Fast Dissolving Tablet of Hibiscus rosa-sinensis Leaf Mucilage as Superdisintegrant

Abstract

Natural polymers remain attractive primarily because they are natural products of plants, readily available, inexpensive and capable of multitude of chemical modification. Leaves of Hibiscus rosa-sinensis Linn (family: Malvaceae) contains high proportion of mucilage which can be used as additives in pharmaceutical formulations. The objective of the studide to extract mucilage from the leaves Hibiscus rosa-sinensis and examine the disintegrant property of the dried mucilage to assess its functionality as a pharmaceutical excipient. The Present work was carried out to study the disintergant property of Hibiscus rosa-sinensis mucilage using Imipramine as a model drug. The present work was carried out to develop fast dissolving tablet of Imipramine using natural disintegrant isolated from Hibiscus rosa-sinensis leaves and its efficiency was compared with synthetic superdisintegrant like crosspovidone. Hibiscus rosa-sinensis mucilage was isolated and characterised for its identification by chemical test and micrometric properties. Fast dissolving tablets of Imipramine were formulated by direct compression method using Hibiscus rosa-sinensis mouth feel and compressibility and aspartame as sweetener. The formulated tablets were evaluated for their pre and post compression parameters like tablet hardness, thickness, % friability, wetting time which was found to be in permissible limits. The in vitro disintegration time of tablet formulations containing 6% of mucilage was found to be 24 sec and that of tablet containing 4% of crosspovidone was 42secs. Based upon in vitro disintegration time in vitro drug release studies put and in between were carried out in phosphate buffer p H 6.8 which showed 100% drug release in 12 minutes of F3 formulation containing 6% of mucilage. Stability studies performed on F3 formulation indicated that the prepared tablets remain stable for the period of 90 days and showed no change in in-vitro drug release pattern.